Skip to main content
  • Saved

made a Post

SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction - Cardiovascular Drugs and Therapy

SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction - Cardiovascular Drugs and Therapy

Source :

https://link.springer.com/article/10.1007/s10557-022-07371-7

Results from DELIVER trial and publication of EMPEROR-Preserved with sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with heart failure (HF) with ejection fraction (EF) > 40% represent a significant step forward in the treatment of HF with preserved EF (HFpEF).



Relevance: Results from DELIVER trial and publication of EMPEROR-Preserved with sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with heart failure (HF) with ejection fraction (EF) > 40% represent a significant step forward in the treatment of HF with preserved EF (HFpEF). However, detailed analysis and attenuation of effect at higher EF levels have sparked some doubts about whether empagliflozin is effective across the entire spectrum of EF.